|
1 |
Dr. Karan Kumar |
30-Aug-2023 |
Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, Hatanaka T, Tada T, Kumada T, Kakizaki S, Vogel A. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinicalMedicine. 2023 Sep 1;63. |
|
2 |
Dr. Karan Kumar |
August, 2023 |
Kumar K, Jindal A, Gupta E, Trehanpati N, Shasthry SM, Maiwall R, Arora V, Bhardwaj A, Kumar G, Kumar M, Sarin SK. Long Term HBsAg Responses to Peg-Interferon Alpha-2b in HBeAg Negative Chronic Hepatitis B Patients Developing Clinical Relapse after Stopping Long-Term Nucleos (t) ide Analogue Therapy. Journal of Clinical and Experimental Hepatology. 2023 Aug 23. |
|
3 |
Dr. VA Saraswat |
27-Jul-2023 |
Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Gray R, Lim YS, Chen CJ, Ocama P, Saraswat VA, Desalegn H, Abbas Z. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The Lancet Gastroenterology & Hepatology. 2023 Oct 1;8(10):879-907. |
|
4 |
Dr. Karan Kumar |
15-June-2023 |
Jagdish RK, Roy A, Kumar K, Premkumar M, Sharma M, Rao PN, Reddy DN, Kulkarni AV. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. Frontiers in Medicine. 2023 Jun 15;10:1060073. |
|
5 |
Dr. VA Saraswat |
23-June, 2023 |
Ghany, Marc G. MD, MHSc1; Saraswat, Vivek A. MD, DM, FACG, FINASL, MISG, FSGEI2. Patients With Compensated Hepatitis B Virus-Related Cirrhosis and Low-Level Viremia: Treat or Not to Treat?. The American Journal of Gastroenterology 118(6):p 970-971, June 2023. | DOI: 10.14309/ajg.0000000000002224 |
|
6 |
Dr. VA Saraswat |
05 June, 2023 |
Arora A, Kumar A, Anand AC, Kumar A, Yadav A, Bhagwat A, Mullasari AS, Satwik A, Saraya A, Mehta A, Saraswat VA, Roy D. Position statement from the Indian Society of Gastroenterology, Cardiological Society of India, Indian Academy of Neurology and Vascular Society of India on gastrointestinal bleeding and endoscopic procedures in patients on antiplatelet and/or anticoagulant therapy. Indian Journal of Gastroenterology. 2023 Jun 5:1-5. |
|
7 |
Dr. Karan Kumar |
26-Apr-2023 |
Islam M, Kumar K, Sevak JK, Jindal A, Vyas AK, Ramakrishna G, Kottilil S, Sharma MK, Sarin SK, Trehanpati N. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. Hepatology Communications. 2023 May;7(5). |
|
8 |
Dr. VA Saraswat |
March -2023 |
Duseja A, Singh SP, De A, Madan K, Rao PN, Shukla A, Choudhuri G, Saigal S, Shalimar, Arora A, Anand AC, Das A, Kumar A, Eapen CE, Devadas K, Shenoy KT, Panigrahi M, Wadhawan M, Rathi M, Kumar M, Choudhary NS, Saraf N, Nath P, Kar S, Alam S, Shah S, Nijhawan S, Acharya SK, Aggarwal V, Saraswat VA, Chawla YK. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7. PMID: 36950481; PMCID: PMC10025685. |
|
9 |
Dr. VA Saraswat |
March-2023 |
Duseja A, Singh SP, De A, Madan K, Rao PN, Shukla A, Choudhuri GC, Saigal S, Arora A, Anand AC,
Saraswat VA Das A. Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of non-alcoholic fatty liver Disease (NAFLD). Journal of clinical and experimental hepatology. 2022 Dec 7. |
|
10 |
Dr. Karan Kumar |
10-Feb-2023 |
Kulkarni AV, Krishna V, Kumar K, Sharma M, Patodiya B, Khan A, Shaik S, Pasumarthy A, Chhabra P, Da PK, Saraswat VA. Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience. Journal of Clinical and Experimental Hepatology. 2023 Feb 10. |
|
11 |
Dr. VA Saraswat
Dr. Karan Kumar |
Jan-2023 |
Book Chapter in - Expanding Horizons for HBV Therapy in 2022 |
|
12 |
Dr. Karan Kumar |
Sept-2022 |
Pande G, Hatti M, Rai MK, Rai P, Kumar K, Vp K, Nehra A, Kumar S, Ranjan Rout S, Mishra SK, Kumar D. Response guided slow infusion of albumin, vasoconstrictors and furosemide improves ascites mobilization and survival in acute on chronic liver failure: a proof-of-concept study. Journal of Inflammation Research. 2022 Jan 1:5027-39. |
|
13 |
Dr. Karan Kumar |
Aug-2022 |
Kulkarni AV, Premkumar M, Arab JP, Kumar K, Sharma M, Reddy ND, Padaki NR, Reddy RK. Early Diagnosis and Prevention of Infections in Cirrhosis. Semin Liver Dis. 2022 Aug;42(3):293-312. doi: 10.1055/a-1869-7607. Epub 2022 Jun 7. PMID: 35672014. |
|
14 |
Dr. VA Saraswat
Dr. Karan Kumar |
May-2022 |
Kumar K, Kulkarni A, Mahala VK, Saraswat VA. Early prediction of decompensation in cirrhosis-Is it possible without aetiology and portal hypertension?. Liver international: official journal of the International Association for the Study of the Liver. 2022 May;42(5):1206. |
|
15 |
Dr. VA Saraswat |
May-2022 |
Anand V. Kulkarni, Madhumita Premkumar, Karan Kumar Juned, Saraswat VA ,A. Khan, Baqar A. Gora Sowmya Tirumalle, Sameer Shaik, Mithun Sharma, Rajesh Gupta, Nageshwar D. Reddy, Nonselective beta‐blockers reduce mortality in patients with acute‐on‐chronic liver failure, Volume.1:1Page 15–22. May 2022, 10.1053/j.gastro.2020.09.026 |
|
16 |
Dr. VA Saraswat
Dr. Karan Kumar |
May-2022 |
Kumar K, Kulkarni A, Mahala VK, Saraswat VA. Early prediction of decompensation in Cirrhosis-Is it possible without aetiology and portal hypertension? Liver international: official journal of the International Association for the Study of the Liver. 2022 May;42(5):1206. |
|
17 |
Dr. Karan Kumar |
Apr-2022 |
Kulkarni AV, Ravikumar ST, Tevethia H, Premkumar M, Kumar K, Sharma M, Gupta R, Rao PN, Reddy DN. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study. Scientific Reports. 2022 Apr 1;12(1):5503. |
|
18 |
Dr. Karan Kumar |
Apr-2022 |
Kulkarni AV, Hanchanale P, Prakash V, Kalal C, Sharma M, Kumar K, Bishnu S, Kulkarni AV, Anand L, Patwa AK, Kumbar S, Kainth S, Philips CA; Liver Research Club India. Tinospora Cordifolia (Giloy)-Induced Liver Injury During the COVID-19 Pandemic-Multicenter Nationwide Study From India. Hepatol Commun. 2022 Jun;6(6):1289-1300. doi: 10.1002/hep4.1904. Epub 2022 Feb 6. PMID: 35037744; PMCID: PMC9134809. |
|
19 |
Dr. VA Saraswat |
Mar-Apr-2022 |
Saraswat VA, Kumar K. Untangling the Web of Malnutrition, Sarcopenia, and Frailty in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):268-71. |
|
20 |
Dr. VA Saraswat |
Mar-Apr-2022 |
Anand AC, Nandi B, Acharya SK, Arora A, Babu S, Batra Y, Chawla YK, Saraswat VA, Chowdhury A, Chaoudhuri A, Eapen EC, Devarbhavi H. Erratum to ‘Indian National Association for the Study of Liver Consensus Statement on Acute Liver Failure (Part-2): Management of Acute Liver Failure’[J Clin Exp Hepatol 10 (2020) 477-517]. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):729-30. |
|
21 |
Dr. Karan Kumar |
March-2022 |
Kulkarni AV, Kumar K, Candia R, Arab JP, Tevethia HV, Premkumar M, Sharma M, Menon B, Rao GV, Reddy ND, Rao NP. Prophylactic perioperative terlipressin therapy for preventing acute kidney injury in living donor liver transplant recipients: a systematic review and meta-analysis. Journal of Clinical and Experimental Hepatology. 2022 Mar 1;12(2):417-27. |